Evidence suggests that stage at diagnosis, presence and subtype of RET mutation, levels of biomarkers such as calcitonin and carcinoembryonic antigen (CEA), and type of systemic treatment may affect prognosis in advanced/metastatic MTC [11–15]. The gene discussed is CEACAM5; the disease is medullary thyroid gland carcinoma.